Sanofi, UCB secure FDA approval for wider use of Xyzal

08/25/2009 | Forbes

Sanofi-Aventis and UCB received FDA clearance to market once-daily Xyzal as a treatment for indoor allergies and hives in children 6 months and older as well as for outdoor allergies in those older than 2. The product already is approved for children age 6 and older.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA